Consensus document on controversial issues in the diagnosis and treatment of bloodstream infections and endocarditis

International Journal of Infectious Diseases

Volumn 14, Issue SUPPL. 4, 2010, Pages

  Boumis, Evangelo ^a   Gesu, Giovanni ^b   Menichetti, Francesco ^c   Ranieri, Marco ^d   Rinaldi, Mauro ^d   Suter, Fredy ^e   Nicastri, Emanuele ^a,h   Lauria, Francesco N ^a,h   Carosi, Giampiero ^f,h   Moroni, Mauro ^g,h   Ippolito, Giuseppe ^a,h  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e OSPEDALI RIUNITI   (Italy)

^f UNIVERSITY OF BRESCIA   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h GISIG Gruppo Italiano di Studio sulle Infezioni Gravi Coordinating Committee   (Italy)

Author keywords

Bloodstream infections; Endocarditis; Infections of vascular prostheses

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CIPROFLOXACIN; CLOXACILLIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; FUSIDIC ACID; GENTAMICIN; LINEZOLID; MINOCYCLINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

ABSENCE OF SIDE EFFECTS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERICIDAL ACTIVITY; BLOOD CULTURE; BLOODSTREAM INFECTION; CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; CONTINUOUS INFUSION; DIZZINESS; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; ENDOCARDITIS; ENTEROCOCCUS FAECALIS; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HEART VALVE PROSTHESIS; HEART VALVE REPLACEMENT; HUMAN; INTRAVENOUS DRUG ABUSE; ITALY; KIDNEY FAILURE; LOADING DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NONHUMAN; OVERALL SURVIVAL; PRACTICE GUIDELINE; SEPSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, BACTERIAL; ENDOCARDITIS, BACTERIAL; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 78149283586     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2010.05.006     Document Type: Article

References (56)

1. Cuevas O., Cercenado E., Vindel A., Guinea J., Sánchez-Conde M., Sánchez-Somolinos M., et al. Evolution of the antimicrobial resistance of Staphylococcus spp in Spain: five nationwide prevalence studies, 1986 to 2002. Antimicrob Agents Chemother 2004, 48:4240-4245.
2. Klevens R.M., Morrison M.A., Nadle J., Petit S., Gershman K., Ray S., et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007, 298:1763-1771.
3. Smith T.L., Pearson M.L., Wilcox K.R., Cruz C., Lancaster M.V., Robinson-Dunn B., et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999, 340:493-501.
4. Chang S., Sievert D.M., Hageman J.C., Boulton M.L., Tenover F.C., Downes F.P., et al. Vancomycin-Resistant Staphylococcus aureus Investigative Team. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003, 348:1342-1347.
5. Ioannidou S., Tassios P.T., Kotsouili-Tseleni A., Foustoukou M., Legakis N.J., Vatopoulos A. Antibiotic resistance rates and macrolide resistance phenotypes of viridans group streptococci from the oropharynx of healthy Greek children. Int J Antimicrob Agents 2001, 17:195-201.
6. Gordon K.A., Beach M.L., Biedenbach D.J., Jones R.N., Rhomberg P.R., Mutnick A.H. Antimicrobial susceptibility patterns of α-hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis 2002, 43:157-162.
7. Martin G.S., Mannino D.M., Eaton S., Moss M. The epidemiology of sepsis in the United States from 1979 to 2000. N Engl J Med 2003, 348:1546-1554.
8. Dombrovskiy V.Y., Martin A.A., Sunderram J., Paz H.L. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007, 35:1244-1250.
9. Fitzgerald S.F., Kelly C., Humphreys H. Diagnosis and treatment of prosthetic aortic graft infections: confusion and inconsistency in the absence of evidence or consensus. J Antimicrob Chemother 2005, 56:996-999.
10. Baddour L.M. Long-term suppressive antimicrobial therapy for intravascular device-related infections. Am J Med Sci 2001, 322:209-212. Infectious Diseases Society of America's Emerging Infections Network.
11. Atkins D., Best D., Briss P.A., Eccles M., Falck-Ytter Y., Flottorp S., et al. Grading quality of evidence and strength of recommendations. BMJ 2004, 328:1490. GRADE Working Group.
12. Lauria F.N., De Carli G., Nicastri E. Resistant and multi-resistant Gram-positive severe infections: the GISIG working methodology. Int J Infect Dis 2010, 14S:S13-S17.
13. Fortún J., Pérez-Molina J.A., Añón M.T., Martínez-Beltrán J., Loza E., Guerrero A. Right-sided endocarditis caused by Staphylococcus aureus in drug abusers. Antimicrob Agents Chemother 1995, 39:525-528.
14. Fortún J., Navas E., Martínez-Beltrán J., Pérez-Molina J., Martín-Dávila P., Guerrero A., et al. Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. Clin Infect Dis 2001, 33:120-125.
15. Ribera E., Gómez-Jimenez J., Cortes E., del Valle O., Planes A., Gonzalez-Alujas T., et al. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial. Ann Intern Med 1996, 125:969-974.
16. Abrams B., Sklaver A., Hoffman T., Greenman R. Single or combination therapy of staphylococcal endocarditis in intravenous drug abusers. Ann Intern Med 1979, 90:789-791.
17. Gilbert D.N., Wood C.A., Kimbrough R.C. Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. Antimicrob Agents Chemother 1991, 35:79-87. The Infectious Diseases Consortium of Oregon.
18. Huang J.H., Hsu R.B. Treatment of infective endocarditis caused by methicillin-resistant Staphylococcus aureus: teicoplanin versus vancomycin in a retrospective study. Scand J Infect Dis 2008, 40:462-467.
19. Sexton D.J., Tenenbaum M.J., Wilson W.R., Steckelberg J.M., Tice A.D., Gilbert D., et al. Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Clin Infect Dis 1998, 27:1470-1474.
20. Cosgrove S.E., Vigliani G.A., Fowler V.G., Abrutyn E., Corey G.R., Levine D.P., et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009, 48:713-721.
21. Fowler V.G., Boucher H.W., Corey G.R., Abrutyn E., Karchmer A.W., Rupp M.E., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006, 355:653-665.
22. Rehm S.J., Boucher H., Levine D., Campion M., Eisenstein B.I., Vigliani G.A., et al. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother 2008, 62:1413-1421.
23. Falagas M.E., Manta K.G., Ntziora F., Vardakas K.Z. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother 2006, 58:273-280.
24. Muñoz P., Rodríguez-Creixéms M., Moreno M., Marín M., Ramallo V., Bouza E. Linezolid therapy for infective endocarditis. Clin Microbiol Infect 2007, 13:211-215. GAME Study Group.
25. Falagas M.E., Giannopoulou K.P., Ntziora F., Vardakas K.Z. Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. J Antimicrob Chemother 2007, 60:7-19.
26. Howden B.P., Ward P.B., Charles P.G., Korman T.M., Fuller A., du Cros P., et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004, 38:521-528.
27. Sgarabotto D., Cusinato R., Narne E., Scano F., Zignol M., Gambino A., et al. Synercid plus vancomycin for the treatment of severe methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci infections: evaluation of 5 cases. Scand J Infect Dis 2002, 34:122-126.
28. Arias C.A., Torres H.A., Singh K.V., Panesso D., Moore J., Wanger A., et al. Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin Infect Dis 2007, 45:1343-1346.
29. Cunha B.A., Mickail N., Eisenstein L. E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin. Heart Lung 2007, 36:456-461.
30. Cunha B.A., Krol V., Kodali V. Methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE) in a patient with Job's syndrome (hyperimmunoglobulin E syndrome) successfully treated with linezolid and high-dose daptomycin. Heart Lung 2008, 37:72-75.
31. Matsumura S., Simor A.E. Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination. Clin Infect Dis 1998, 27:1554-1556.
32. Viale P., Scolari C., Colombini P., Cristini F., Cadeo B., Pagani L. Sequential regimen for early post-surgical infective endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA), unresponsive to standard antibiotic therapy: a case report. J Chemother 2002, 14:526-529.
33. Zinkernagel A.S., Speck R.F., Ruef C., Zingg W., Berger-Bachi B., Springer B. Rapidly destructive Staphylococcus epidermidis endocarditis. Infection 2005, 33:148-150.
34. Konstantinov I.E., Zehr K.J. Aortic root replacement in a patient with vancomycin-resistant Enterococcus faecium endocarditis and leukemia. Chest 2001, 120:1744-1746.
35. Mergenhagen K.A., Pasko M.T. Daptomycin use after vancomycin-induced neutropenia in a patient with left-sided endocarditis. Ann Pharmacother 2007, 41:1531-1535.
36. Chesi G., Colli A., Mestres C.A., Gambarati G., Boni F., Gherli T. Multiresistant-MRSA tricuspid valve infective endocarditis with ancient osteomyelitis locus. BMC Infect Dis 2006, 6:124.
37. Liu C.Y., Wang J.L., Huang Y.T., Hsueh P.R. Development of multiple lung abscesses during daptomycin treatment for right-sided endocarditis caused by methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 2008, 32:544-545.
38. Tenover F.C., Sinner S.W., Segal R.E., Huang V., Alexandre S.S., McGowan J.E., et al. Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy. Int J Antimicrob Agents 2009, 33:564-568.
39. Babcock H.M., Ritchie D.J., Christiansen E., Starlin R., Little R., Stanley S. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis 2001, 32:1373-1375.
40. Sakoulas G., Rose W., Rybak M.J., Pillai S., Alder J., Moellering R.C., et al. Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin. J Clin Microbiol 2008, 46:220-224.
41. Schwartz B.S., Ngo P.D., Guglielmo B.J. Daptomycin treatment failure for vancomycin-resistant Enterococcus faecium infective endocarditis: impact of protein binding?. Ann Pharmacother 2008, 42:289-290.
42. Huang Y.T., Hsiao C.H., Liao C.H., Lee C.W., Hsueh P.R. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan. J Clin Microbiol 2008, 46:1132-1136.
43. Lemaire S., Kosowska-Shick K., Julian K., Tulkens P.M., Van Bambeke F., Appelbaum P.C. Activities of anti-staphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis. Clin Microbiol Infect 2008, 14:766-777.
44. Chow J.W., Davidson A., Sanford E., Zervos M.J. Superinfection with Enterococcus faecalis during quinupristin/dalfopristin therapy. Clin Infect Dis 1997, 24:91-92.
45. Pistella E., Campanile F., Bongiorno D., Stefani S., Di Nucci G.D., Serra P., et al. Successful treatment of disseminated cerebritis complicating methicillin-resistant Staphylococcus aureus endocarditis unresponsive to vancomycin therapy with linezolid. Scand J Infect Dis 2004, 36:222-225.
46. Shah M., Murillo J.L. Successful treatment of Corynebacterium striatum endocarditis with daptomycin plus rifampin. Ann Pharmacother 2005, 39:1741-1744.
47. Shorr A.F., Kunkel M.J., Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 2005, 56:923-929.
48. Stevens D.L., Herr D., Lampiris H., Hunt J.L., Batts D.H., Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002, 34:1481-1490.
49. Wilcox M., Nathwani D., Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J Antimicrob Chemother 2004, 53:335-344.
50. Wilcox M.H., Tack K.J., Bouza E., Herr D.L., Ruf B.R., Ijzerman M.M., et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 2009, 48:203-212.
51. Cepeda J.A., Whitehouse T., Cooper B., Hails J., Jones K., Kwaku F., et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother 2004, 53:345-355.
52. Adembri C., Fallani S., Cassetta M.I., Arrigucci S., Ottaviano A., Pecile P., et al. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents 2008, 31:122-129.
53. Linden P.K., Pasculle A.W., McDevitt D., Kramer D.J. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort. J Antimicrob Chemother 1997, 39(Suppl A):145-151.
54. Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65 (supplementary appendix available at ). http://content.nejm.org/cgi/content/full/355/7/653/DC1.
55. Fernández de Gatta M.M., Calvo M.V., Hernández J.M., Caballero D., San Miguel J.F., Domínguez-Gil A. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Clin Pharmacol Ther 1996, 60:332-340.
56. Welty T.E., Copa A.K. Impact of vancomycin therapeutic drug monitoring on patient care. Ann Pharmacother 1994, 28:1335-1339.